Clinical Trials Directory

Trials / Completed

CompletedNCT05620056

A Population-based Study of Drug Exposures and Adverse Pregnancy Outcomes in China (DEEP)

Status
Completed
Phase
Study type
Observational
Enrollment
564,760 (actual)
Sponsor
West China Hospital · Academic / Other
Sex
Female
Age
14 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes.

Detailed description

The DEEP cohort is the first population-based cohort of pregnant population in China that longitudinally documents drug uses throughout the pregnancy life course and adverse pregnancy outcomes. The main goal of the study aims to monitor and evaluate the safety of drug use through the pregnancy life course in the Chinese setting. The DEEP cohort is developed primarily based on the population-based data platforms in Xiamen, a municipal city of 5 million population in southeast China. Based on these data platforms, a pregnancy-centered registry was developed that documented health care services and outcomes in the maternal and other departments. For identifying drug uses, a drug prescription database was specifically developed by using electronic healthcare records documented in the platforms across the primary, secondary and tertiary hospitals. By linking the pregnancy registry and prescription database through a unique identifier, the DEEP cohort was developed. All the pregnant women and their offspring in Xiamen are provided with health care and followed up according to standard protocols in the region, including antenatal care, delivery care, postpartum follow-up and childhood follow-ups. The primary adverse outcomes - congenital malformations - are collected using a standardized Case Report Form.

Conditions

Interventions

TypeNameDescription
DRUGchemicals drugs, biological products, patent Chinese Medicines, Chinese herbsmedication (i.e., chemicals drugs, biological products, patent Chinese Medicines, Chinese herbs ) exposure through the pregnancy life course

Timeline

Start date
2013-01-01
Primary completion
2021-12-31
Completion
2022-11-01
First posted
2022-11-17
Last updated
2022-11-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05620056. Inclusion in this directory is not an endorsement.